Dealbook Online

By MARK SCOTT and MICHAEL J. de la MERCED

Published: March 27, 2012

QUEEN'S BANKER FINED British regulators on Monday fined the private bank Coutts £8.75 million ($13.9 million) for failing to follow standards intended to fight money laundering. The fine is the largest ever for a British firm for issues connected to financial crime.

The Financial Services Authority of Britain said Coutts, which is part of the nationalized Royal Bank of Scotland and provides banking services to Queen Elizabeth II, had not applied rigorous controls when dealing with so-called high-risk customers. In November, British authorities fined Coutts £6.3 million for improperly selling bonds issued by the American International Group. MARK SCOTT

ON THE BLOCK The European private equity firm Permira is exploring a sale of the Iglo Group, a frozen food company, for as much as 3 billion euros ($4 billion), according to people briefed on the matter. Iglo, which Permira bought from Unilever for 1.7 billion euros in 2006, markets several brands in Europe, including the Birds Eye brand. Permira has hired Credit Suisse to oversee the potential sale, though discussions remain at an early stage. MARK SCOTT

MAC AND CHEESE AND AN I.P.O. Annie's Inc., the pasta maker, has raised the price range for its initial public offering this week, according to a filing on Monday. The company now expects to price its shares between $16 and $18, up from a previous range of $14 to $16.

Annie's, known for its organic products (and its rabbit mascot), plans to sell five million shares. At the midpoint of its new range, Annie's would raise about $85 million. The bulk of the proceeds will go to Annie's investors selling shares in the offering. Among those investors is Solera Capital, which owns a 90.5 percent stake. MICHAEL J. de la MERCED

STILL IN THE HUNT Roche Holding, the Swiss drug giant, said on Monday that it was extending the deadline to April 20 for its $5.7 billion hostile takeover bid for Illumina, a provider of genetic analysis services.

This is the second time that Roche has pushed back the deadline. After making its initial approach in late January, Roche subsequently extended the deadline to last Friday. The board of Illumina has called Roche's offer ''grossly inadequate.'' MARK SCOTT